- TRADE NAME: Seysara (Allergan)
- INDICATIONS: indicated for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris in patients 9 years of age and older.
- CLASS: Antibiotic, Antibiotic; tetracycline
- HALF-LIFE: 21–22 hours
- FDA APPROVAL DATE: 10/01/2018
- CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:
Acitretin, Isotretinoin - PREGNANCY: may cause fetal harm
- See adverse reactions attributed to class:
Please login to view the rest of this drug profile.
Page last updated 06/05/2025
